New Drug Combinations Improve Survival in Lung Cancer

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Category: smallbizSource: wsjApr 17th, 2018

AstraZeneca"s drug extending survival rate in lung cancer patients

Using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity.....»»

Category: topSource: business-standardMay 26th, 2018

Immune therapy doubles lung cancer survival rate

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

Category: topSource: bizjournalsApr 17th, 2018

Merck shares rise after beating rivals" lung cancer results

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Category: topSource: marketwatchApr 16th, 2018

Bristol-Myers Posts Data on Empliciti, China Approves Opdivo

Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer. Br.....»»

Category: dealsSource: nytJun 18th, 2018

Lung Cancer Drug From Merck Solidifies Lead in Crowded Field - Bloomberg

KDALLung Cancer Drug From Merck Solidifies Lead in Crowded FieldBloombergIn the race to.....»»

Category: topSource: googlenewsJun 3rd, 2018

Pfizer"s Xalkori Gets Breakthrough Status for New Indications

Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications. Pfi.....»»

Category: dealsSource: nytMay 30th, 2018

Brainstorm Health: Puerto Rico Maria Deaths, Roche Lung Cancer Drug, Planned Parenthood Setback

Brainstorm Health Daily: May 29, 2018 Hurricane season does not officially begin until Friday, June 1--though that start date is somewhat artificial as Subtropical Storm Alberto made clear yesterday--driving its way across .....»»

Category: europeSource: fortuneMay 29th, 2018

Roche"s Tecentriq Study Meets Co-Primary Endpoints for NSCLC

Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer. Roche RHHBY announced that the phase III study, IMpower130 on immunot.....»»

Category: smallbizSource: nytMay 29th, 2018

AstraZeneca"s Imfinzi Improves Survival in Lung Cancer Study


Category: topSource: redinewsMay 28th, 2018

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates......»»

Category: blogSource: 247wallstApr 17th, 2018

Brainstorm Health: Merck’s Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

Brainstorm Health Daily: April 16, 2018 Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be r.....»»

Category: europeSource: fortuneApr 16th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

Shares of the biotech company Advaxis Inc. surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The clinical hol.....»»

Category: topSource: marketwatchJul 13th, 2018

OncoCyte (OCX) Stock Skyrockets on Lung Cancer Test Study Results

InvestorPlace - Stock Market News, Stock Advice & Tradi.....»»

Category: topSource: investorplaceJul 10th, 2018

Celgene reports positive results in late-stage trial of treatment for breast cancer

Celgene Corp. reported positive results from a late-stage trial of a treatment for breast cancer Tuesday, saying the trial met its co-primary endpoint of progression-free survival. The trial, whic.....»»

Category: topSource: marketwatchJul 10th, 2018

Hitting cancer early: AstraZeneca"s bid to outmaneuver rivals

LONDON (Reuters) - AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit......»»

Category: topSource: reutersJul 6th, 2018

Merck"s Keytruda Gets Priority Review in Difficult Lung Cancer

Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decisio.....»»

Category: worldSource: nytJul 3rd, 2018

Boulder biotech"s melanoma treatment gets FDA approval

A Boulder biotech's combination treatment for a form of skin cancer was approved this week by the U.S. Food and Drug Administration. Array BioPharma Inc. (Nasdaq: ARRY) said its Braftovi capsules in combination with Mektovi tablets has been approved .....»»

Category: topSource: bizjournalsJun 29th, 2018